NEWS
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024.
The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression.
Key points:
- Median age: 71 years (range: 51-85)
- 78% of participants ≥65 years old
- 50% female, 94% Caucasian
- 67% with mild cognitive impairment, 33% with mild dementia
- 59% heterozygous APOE e4 carriers
- All participants confirmed amyloid-positive
Results are expected in Q4 2024, with a long-term extension study ongoing. The baseline data confirm a representative study population for testing AL002's effects in early AD.
- Median age: 71 years (range: 51-85)
- 78% of participants ≥65 years old
- 50% female, 94% Caucasian
- 67% with mild cognitive impairment, 33% with mild dementia
- 59% heterozygous APOE e4 carriers
- All participants confirmed amyloid-positive
Results are expected in Q4 2024, with a long-term extension study ongoing. The baseline data confirm a representative study population for testing AL002's effects in early AD.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1170Followers
73Following
8186Visitors
Follow